With regard to the supraclavicular node in my neck that is
once again growing and showing active metastatic activity, Dr. Ferrera thought
that I could also wait and see if that continued to grow. It’s not causing any
problems right now, and it has a history of growing and shrinking.
Alternatively, she thought that it could be treated with cyberknife radiation,
since it is the only tumor of significance currently showing up on my PET scan.
She also thought that there was the possibility that the lung tumor could also
be zapped with Cyberknife radiation if it continues to grow. Before making a
decision, she wanted to see what NIH said.
On Monday, December 10, I met with Dr. Andrea Apolo and her
team at NIH’s NCI in Bethesda Maryland. She’s followed my case since April 2012,
and I think that she is one of the most knowledgeable doctors in the world
regarding current and cutting-edge treatments for metastatic bladder cancer. After
I was screed by one of her fellows, she came in with her team to review my
options. She said that she’d recently talked with Dr. Noah Hahn about my case, and
that she said with a smile that she was not very impressed by my tumors. I told
her that I was happy to hear that. (You do not want to have an oncologist tell
you she is impressed by your tumors.) She didn’t think that I needed to enter a
new clinical trial right now (yay!). She asked that I send her a copy of every
scan so she could continue to follow my case, and we’d keep in touch by phone
or email. If and when it’s time to start a new clinical trial – most likely a combination
drug therapy trial – we’ll sort out the best drugs and which location at that
time.
For now, Dr. Apolo recommended that I continue with my
Opdivo treatments and taking a wait and see approach, with regular CT scans. I
told her about Dr. Ferrera’s idea of having cyberknife radiation, and Dr. Apolo
said that she was not opposed to the idea. Usually she would not recommend
zapping individual metastatic tumors, but in view of my young age and otherwise
decent health, radiation might be an option. She thought that it need not be
immediate, however – I could do it in January or after my next CT. I thanked
her as we hugged at the end of my appointment. I am so fortunate to have such a
skilled practitioner as part of my team.
On Wednesday, I went into Kaiser’s Tysons Corner facility
for nivolumab infusion #55. As usual, it was unremarkable: IV placement, 30
minute drug push, and done. It likely will be the last time that I’ll get an
infusion in Virginia, since effective next year I’ll be changing to a
Utah-based insurance policy. Notwithstanding my recent adventure with Kaiser in
Denver, I’ve come to appreciate the care I’ve received of the past three years
from Kaiser. When I first enrolled in Kaiser’s Medicare Advantage program in
2016 after formally retiring from my law firm, Kaiser noted that I was in a
clinical trial with Johns Hopkins and also enrolled me in the Kaiser Family
Foundation medical assistance program, which covered all of my deductibles and
copays. So for the past three years I have not paid a penny for any of my
treatments – Opdivo, or scans, or other medications. And the care that I have received
from my Kaiser oncologist (Dr. Ferrera) and my primary care provider (Dr. SummerAbdel-Megeed) has been as good as any doctor I’ve seen.
But alas, Kaiser is not in Utah, where I’m now spending most
of my time. Shopping for a new Medicare Advantage policy was a bit of a pain. I
first had to find a policy that covered the oncologist that I intend to see
(Dr. Ben Maugham). Then I needed to find out who much I’d be paying for
coverage, which is the sum of my monthly cost, the copays, the deductibles,
coinsurance, and whether Opdivo was covered. As near as I could tell, Opdivo is
not on any of the insurance company formulary lists of approved drugs. To find
out whether it is covered or not, I’ve had to call each company, educate the
rep about the drug, and learn the coverage limits. I’ve learned that Opdivo is
not considered a Medicare Part D drug, because it’s given by infusion in a
doctor’s office. That makes it a Medicare Part B procedure. The drug component
of the procedure is subject to an 80/20 split, with me paying the 20%, up to
the amount of the annual out-of-pocket maximum. The policy that I finally
settled on has an OOP max of $4900, which I’ll probably hit in the first month
or two of 2019.
This morning I met with Dr. Ferrera. I’d already sent her an
email updating her with Dr. Apolo’s thoughts. We considered setting up the
cyberknife appointment for next week, but I decided to wait until after the
holidays and will follow up with my new doctors in Utah next year. I thanked
her for her outstanding care and coordination with my other doctors. We hugged
and I told her I’d give her a shout out in my blog. Everybody now: Yay for Dr.
Ferrera!